Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / zimvie reports first quarter 2024 financial results mwn benzinga


ZIMV - ZimVie Reports First Quarter 2024 Financial Results | Benzinga

    • Third Party Net Sales from Continuing Operations of $118.2 million
    • Net Loss from Continuing Operations of ($11.5) million; Net Loss margin of (9.7%)
    • Adjusted EBITDA[1] from Continuing Operations of $12.5 million; Adjusted EBITDA[1] margin of 10.5%
    • Completed sale of spine business for $375 million and repaid $275 million of debt on April 1, 2024

    PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call today, May 8, 2024, at 4:30 p.m. Eastern Time.

    "We have driven great progress in 2024 to date, successfully engaging with our dental customers and advancing our innovative product portfolio," said Vafa Jamali, President and Chief Executive Officer. "We are also delivering on our goal to reshape the financial profile of our business. We recently paid down $275 million of debt and re-focused our organization as a pure-play dental company with a comprehensive and industry leading portfolio."

    First Quarter 2024 Financial Results: Continuing Operations

    Third party net sales for the first quarter of 2024 were $118.2 million, a decrease of 1.6% on a reported basis and 1.4% in constant currency[1], versus the first quarter of 2023.

    Net loss for the first quarter of 2024 was ($11.5) million, a reduction of $4.9 million versus a net loss of ($16.4) million in the first quarter of 2023. Net loss margin for the first quarter of 2024 was 9.7% of third party net sales, an increase of 390 basis points over the prior year.

    Adjusted net income[1] for the first quarter of 2024 was $2.2 million, an increase of $1.9 million versus the first quarter of 2023.

    Basic and diluted EPS were ($0.42) and adjusted diluted EPS[1] was $0.08 for the first quarter of 2024. Weighted average shares outstanding for both basic and adjusted diluted EPS was 27.1 million.

    Adjusted EBITDA[1] for the first quarter of 2024 was $12.5 million, or 10.5% of third party net sales, an increase of $1.8 million or 170 basis points versus the first quarter of 2023.

    Full Year 2024 Continuing Operations Financial Guidance:

    Projected Year Ending December 31, 2024
    Guidance
    Net Sales
    $450M to $460M
    Adjusted EBITDA[2]
    $60M to $65M
    Adjusted EPS[2]
    $0.55 to $0.70

    [1] This is a non-GAAP financial measure. Refer to "Note on Non-GAAP Financial Measures" and the reconciliations in this release for further information.

    [2] This is a non-GAAP financial measure for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. Refer to "Forward-Looking Non-GAAP Financial Measures" in this release, which identifies the information that is unavailable without unreasonable efforts and provides additional information. It is probable that this forward-looking non-GAAP financial measure may be materially different from the corresponding GAAP financial measure. 

    Conference Call

    ZimVie will host a conference call today, May 8, 2024, at 4:30 p.m. ET to discuss its first quarter 2024 financial results. To access the call, please register online at https://investor.zimvie.com/events-presentations/event-calendar. A live and archived audio webcast will also be available on this site.

    About ZimVie

    ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

    Note on Non-GAAP Financial Measures

    This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.

    Adjusted EBITDA is a non-GAAP financial measure provided in this release for certain periods and is calculated by excluding certain items from net income/loss from Continuing Operations on a GAAP basis, as detailed in the reconciliations presented later in this press release. Adjusted EBITDA margin is Adjusted EBITDA divided by third party net sales from Continuing Operations for the applicable period.

    Sales change information in this release is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales from Continuing Operations, as applicable, at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.

    Net income (loss) and diluted earnings (loss) per share in this release are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted net income (loss) and adjusted diluted earnings (loss) per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.

    Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are included in this press release.

    Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.

    Forward-Looking Non-GAAP Financial Measures

    This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2024. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," "sees," "seeks," "should," "could," "would," "predicts," "potential," "strategy," "future," "opportunity," "work toward," "intends," "guidance," "confidence," "positioned," "design," "strive," "continue," "track," "look forward to," "optimistic" and similar expressions to identify forward-looking statements. All statements other than statements of historical or current fact are or may be deemed to be forward-looking statements. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations; the effects of global pandemics and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. You are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

    Media Contact Information:

    ZimVie
    Allison Johnson • Allison.Johnson@ZimVie.com
    (774) 266-8046

    Grace Flowers • Grace.Flowers@ZimVie.com
    (561) 319-6130

    Investor Contact Information:

    Gilmartin Group LLC
    Marissa Bych • Marissa@gilmartinir.com

    ZIMVIE INC.
    CONSOLIDATED STATEMENT OF OPERATIONS
    (in thousands, except per share data)
     
     
    (unaudited)
     
    For the Three Months Ended
    March 31,
     
    2024
    2023
    Net Sales
     
     
    Third party, net
    $
    118,195
     
    $
    120,170
     
    Related party, net
     
     
     
    236
     
    Total Net Sales
     
    118,195
     
     
    120,406
     
    Cost of products sold, excluding intangible asset amortization
     
    (44,258
    )
     
    (42,875
    )
    Related party cost of products sold, excluding intangible asset amortization
     
     
     
    (231
    )
    Intangible asset amortization
     
    (6,022
    )
     
    (6,794
    )
    Research and development
     
    (6,701
    )
     
    (7,206
    )
    Selling, general and administrative
     
    (60,330
    )
     
    (66,973
    )
    Restructuring and other cost reduction initiatives
     
    (2,579
    )
     
    (1,172
    )
    Acquisition, integration, divestiture and related
     
    (1,037
    )
     
    (1,342
    )
    Operating expenses
     
    (120,927
    )
     
    (126,593
    )
    Operating Loss
     
    (2,732
    )
     
    (6,187
    )
    Other expense, net
     
    (311
    )
     
    (30
    )
    Interest expense, net
     
    (4,366
    )
     
    (5,075
    )
    Loss from continuing operations before income taxes
     
    (7,409
    )
     
    (11,292
    )
    Provision for income taxes from continuing operations
     
    (4,074
    )
     
    (5,077
    )
    Net Loss from Continuing Operations of ZimVie Inc.
     
    (11,483
    )
     
    (16,369
    )
    Earnings (Loss) from discontinued operations, net of tax
     
    3,722
     
     
    (13,599
    )
    Net Loss of ZimVie Inc.
    $
    (7,761
    )
    $
    (29,968
    )
     
     
     
    Basic (Loss) Earnings Per Common Share:
     
     
    Continuing operations
    $
    (0.42
    )
    $
    (0.62
    )
    Discontinued operations
     
    0.13
     
     
    (0.52
    )
    Net Loss
    $
    (0.29
    )
    $
    (1.14
    )
     
     
     
    Diluted (Loss) Earnings Per Common Share
     
     
    Continuing operations
    $
    (0.42
    )
    $
    (0.62
    )
    Discontinued operations
     
    0.13
     
     
    (0.52
    )
    Net Loss
    $
    (0.29
    )
    $
    (1.14
    )
     
     
     
     
     
     
     


    ZIMVIE INC.
    CONSOLIDATED BALANCE SHEETS
    (in thousands, except per share data)
     
     
    As of
     
    March 31, 2024
    December 31, 2023
    ASSETS
     
     
    Current Assets:
     
     
    Cash and cash equivalents
    $
    43,528
     
    $
    71,511
     
    Accounts receivable, less allowance for credit losses
     
    68,931
     
     
    65,168
     
    Inventories
     
    77,235
     
     
    79,600
     
    Prepaid expenses and other current assets
     
    17,132
     
     
    23,825
     
    Current assets of discontinued operations
     
    248,315
     
     
    242,773
     
    Total Current Assets
     
    455,141
     
     
    482,877
     
    Property, plant and equipment, net
     
    52,120
     
     
    54,167
     
    Goodwill
     
    260,356
     
     
    262,111
     
    Intangible assets, net
     
    109,480
     
     
    114,354
     
    Other assets
     
    27,016
     
     
    26,747
     
    Noncurrent assets of discontinued operations
     
    267,494
     
     
    265,089
     
    Total Assets
    $
    1,171,607
     
    $
    1,205,345
     
    LIABILITIES AND EQUITY
     
     
    Current Liabilities:
     
     
    Accounts payable
    $
    26,955
     
    $
    27,785
     
    Income taxes payable
     
    4,382
     
     
    2,863
     
    Other current liabilities
     
    62,419
     
     
    67,108
     
    Current portion of long-term debt
     
    7,013
     
     
     
    Current liabilities of discontinued operations
     
    68,879
     
     
    75,858
     
    Total Current Liabilities
     
    169,648
     
     
    173,614
     
    Deferred income taxes
     
    165
     
     
    265
     
    Lease liability
     
    9,795
     
     
    9,080
     
    Other long-term liabilities
     
    9,340
     
     
    9,055
     
    Non-current portion of debt
     
    502,056
     
     
    508,797
     
    Noncurrent liabilities of discontinued operations
     
    92,274
     
     
    95,041
     
    Total Liabilities
     
    783,278
     
     
    795,852
     
    Commitments and Contingencies
     
     
    Stockholders' Equity:
     
     
    Common stock, $0.01 par value, 150,000 shares authorized Shares, issued and outstanding, of 27,273 and 27,076, respectively
     

    Full story available on Benzinga.com

  • Stock Information

    Company Name: ZimVie Inc.
    Stock Symbol: ZIMV
    Market: NASDAQ
    Website: zimvie.com

    Menu

    ZIMV ZIMV Quote ZIMV Short ZIMV News ZIMV Articles ZIMV Message Board
    Get ZIMV Alerts

    News, Short Squeeze, Breakout and More Instantly...